Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stock closed at $19.98 on 3/12/24 after a major decline of -17.2%. Moreover, trading volume in this decline was exceptionally high at 408% of normal. The stock has declined -15.9% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
ACAD is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Acadia Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Acadia Pharmaceuticals has a slightly negative Power Rating of 33 and a poor Appreciation Score of 16, and the Lowest Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment